Changes in the pharyngeal and nasal microbiota in pediatric patients with adenotonsillar hypertrophy.

adenotonsillar hypertrophy nasal microbiota pharyngeal microbiota probiotics upper airway pathobionts

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
09 Sep 2024
Historique:
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: aheadofprint

Résumé

The present study aimed to investigate the pharyngeal and nasal microbiota composition in children with adenotonsillar hypertrophy (AH) and assess longitudinal alterations in both microbiota after a probiotic oral spray treatment. A cohort of 57 AH patients were enrolled and randomly assigned to the probiotic and placebo groups for a 5-month treatment course. Pharyngeal and nasal swabs were collected before and after treatment and analyzed by 16S rRNA-based metataxonomics and axenic cultures for pathobiont identification. 16S rRNA sequences from pharyngeal and nasal swabs of 65 healthy children (HC) were used as microbiota reference profiles. We found that the pharyngeal and nasal microbiota of AH children were similar. When compared to HC, we observed an increase of the genera Adenotonsillar hypertrophy (AH) is considered the main cause of breathing disorders during sleep in children. AH patients, after significant morbidity and often multiple courses of antibiotics, often proceed to tonsillectomy and/or adenoidectomy. Given the potential risks associated with these procedures, there is a growing interest in the use of nonsurgical adjuvant therapies, such as probiotics, that could potentially reduce their need for surgical intervention. In this study, we investigated the pharyngeal and nasal microbiota in patients with AH compared with healthy children. Furthermore, we tested the effects of probiotic spray administration on both disease symptoms and microbiota profiles, to evaluate the possible use of this microbial therapy as an adjuvant for AH patients.

Identifiants

pubmed: 39248478
doi: 10.1128/spectrum.00728-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0072824

Auteurs

Federica Del Chierico (F)

Research Unit of Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Antonia Piazzesi (A)

Research Unit of Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Ersilia Vita Fiscarelli (EV)

Research Unit of Diagnostical and Management Innovations, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Maria Vittoria Ristori (MV)

Research Unit of Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Ilaria Pirona (I)

GenomeUp SRL, Rome, Italy.

Alessandra Russo (A)

Unit of Microbiomics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Nicoletta Citerà (N)

Research Unit of Diagnostical and Management Innovations, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Gabriele Macari (G)

GenomeUp SRL, Rome, Italy.

Sara Santarsiero (S)

Unit of Otorhinolaryngology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Fabrizio Bianco (F)

Quality Team Studi Clinici, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Valeria Antenucci (V)

Modelli Innovativi di Regolamentazione in Pediatria, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Valerio Damiani (V)

Medical Department, DMG Italia SRL, Pomezia, Italy.

Luigi Mercuri (L)

Medical Department, DMG Italia SRL, Pomezia, Italy.

Giovanni Carlo De Vincentis (GC)

Unit of Otorhinolaryngology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Lorenza Putignani (L)

Unit of Microbiomics and Research Unit of Microbiome, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.

Classifications MeSH